Breast Cancer Gene Patent Resolved
WASHINGTON--The National Institutes of Health, University of Utah, and Myriad Genetics, Inc. have resolved issues involving patenting of the BRCA1 breast cancer gene by agreeing that scientists from all three institutions should be named as joint inventors in current patent applications. The agreement also ensures that exclusive, worldwide commercial rights are retained by Myriad and its licensees, Eli Lilly and Company and Hybritech Incorporated.
WASHINGTON--The National Institutes of Health, University of Utah,and Myriad Genetics, Inc. have resolved issues involving patentingof the BRCA1 breast cancer gene by agreeing that scientists fromall three institutions should be named as joint inventors in currentpatent applications. The agreement also ensures that exclusive,worldwide commercial rights are retained by Myriad and its licensees,Eli Lilly and Company and Hybritech Incorporated.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment
June 26th 2025Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.
